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Abstract
Background: Recombinant gp120 (MN-rgp120) was a major component of the AIDSVAX B/E vaccine used in the RV144 trial.
This was the first clinical trial to show that vaccination could prevent HIV infection in humans. A recent RV144 correlates of
protection study found that protection correlated with the presence of antibodies to the V2 domain. It has been proposed
that antibodies to the a4b7 binding site in the V2 domain might prevent HIV-1 infection by blocking the ability of virions to
recognize a4b7 on activated T-cells. In this study we investigated the specificity of monoclonal antibodies (MAbs) to the V2
domain of MN-rgp120 and examined the possibility that these antibodies could inhibit the binding of MN-rgp120 to the
a4b7 integrin.
Methodology/Principal Findings: Nine MAbs to the V2 domain were isolated from mice immunized with recombinant
envelope proteins. The ability of these MAbs to inhibit HIV infection, block the binding of gp120 to CD4, and block the
binding of MN-rgp120 to the a4b7 integrin was measured. Mutational analysis showed that eight of the MAbs recognized
two immunodominant clusters of amino acids (166–168 and 178–183) located at either end of the C strand within the four-
strand anti-parallel sheet structure comprising the V1/V2 domain.
Conclusions/Significance: These studies showed that the antigenic structure of the V2 domain is exceedingly complex and
that MAbs isolated from mice immunized with MN-rgp120 exhibited a high level of strain specificity compared to MAbs to
the V2 domain isolated from HIV-infected humans. We found that immunization with MN-rgp120 readily elicits antibodies
to the V2 domain and some of these were able to block the binding of MN-rgp120 to the a4b7 integrin.
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Introduction
Recombinant gp120 from the MN strain of HIV-1 (MN-
rgp120) has been investigated as a candidate HIV-1 vaccine to
elicit protective antibody responses [1–4]. Two bivalent HIV-1
subunit vaccines, AIDSVAX B/B and AIDSVAX B/E, each
containing MN-rgp120, have been developed for use in North
America and Thailand, respectively [5,6]. Both vaccines have now
been tested in large scale Phase 3 trials alone, or in combination
with vaccines such as vCP1521 designed to stimulate cellular
immune responses [7]. In the VAX003 and VAX004 trials (1998–
2003), immunization with these vaccines was ineffective in
preventing new HIV-1 infections in cohorts of injection drug
users (IDUs) and men who had sex with men (MSMs) [8,9].
However, the RV144 clinical trial showed that a prime/boost
immunization regimen, involving priming immunizations with a
recombinant canarypox vector vCP1521 followed by booster
immunizations with AIDSVAX B/E, provided modest but
significant protection from heterosexual HIV-1 transmission [7].
This trial provided the first evidence that vaccination can prevent
HIV-1 infection in humans. In order to establish a correlate of
protection, there is renewed interest in defining the specificity of
the antibody response to the vaccine immunogens, including MN-
rgp120. Initial analysis of sera using the TZM-bl virus neutrali-
zation assay [10] failed to document a correlation between the
level of virus neutralizing antibodies and protection [11,12]. As a
consequence, multiple investigators have begun to consider the
possibility that antibodies might confer protection in vivo by means
other than direct virus neutralization. In principle, non-neutral-
izing antibodies might confer protection by effectively lowering the
probability of infection from transmitted virus inocula. Several
distinct mechanisms have been proposed by which non-neutral-
izing antibodies to the HIV-1 envelope protein might have a
protective effect. These include inactivation of viruses or virus-
infected cells by antibody-dependent cell-mediated virus inhibition
[13]; aggregation of virions at mucosal surfaces, thus impairing
virus transport across mucosal membranes [14]; or prevention of
viruses from selectively targeting activated CD4
+ T-cells [15].
Recently, antibodies that bind to the V2 domain of the HIV-1
envelope protein gp120 have attracted considerable attention in
connection with the RV144 trial [16]. The V2 domain is known to
play a major role in conformational masking, shielding epitopes
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neutralizing antibodies [17–19]. Two recent studies have reported
that potent neutralizing antibodies in sera from HIV-1 infected
individuals are directed to the V2 domain [20,21]. Moreover, two
extremely potent broadly neutralizing monoclonal antibodies
(MAbs), PG9 and PG16, have been shown to target an epitope
in the V2 domain [22]. Finally, it has been demonstrated that the
V2 domain of gp120 can serve as a ligand for the T-cell associated
integrin, a4b7 [23]. It has been proposed that a4b7 interactions
play a major role in facilitating HIV-1 infection by enabling HIV-
1 virions to target activated CD4+ T-cells. It has been known for
many years that infection of activated CD4+ cells results in
productive HIV-1 infection, whereas infection of un-activated
CD4+ cells is less efficient and typically results in abortive infection
[24–26]. However, until the discovery of the a4b7 receptor
binding site in the V2 domain of gp120, it was not known how
HIV-1 could bypass the vast majority of un-activated CD4+ cells
in humoral circulation and target the few activated CD4+ cells
that could sustain productive infections. The discovery of the a4b7
binding site in gp120 provides a plausible explanation for this
important aspect of HIV-1 biology [15]. Thus, antibodies to the
V2 domain that inhibit the binding of HIV-1 to a4b7 would be
expected to lower the probability of infection and might provide
an explanation for the modest protective effect seen in the RV144
trial.
Results
Monoclonal antibodies to the V2 region of MN-rgp120
A collection of thirty-six monoclonal antibodies, produced in the
mid-1990’s against MN-rgp120 or IIIB-rgp140 [27,28], were
screened for reactivity to the MN-rgp120 V2 domain. For this
purpose, a novel epitope mapping strategy was employed using a
panel of overlapping fragments of MN-rgp120, expressed in
mammalian cells (Figure 1, A–I). As described previously [28],
fragments of gp120 fused to the N-terminus of herpes simplex
virus type 1 glycoprotein D (gD-1), possessing the signal sequence
and a 27 amino acid flag epitope, can be efficiently secreted from
293 cells. Moreover, they often preserve some structural features
such as N-linked glycosylation, disulfide bonds, and epitopes
recognized by conformation-dependent antibodies found on full
length gp120. Initial binding studies showed that nine of the thirty-
six MAbs bound to MN-rgp120 fragments F–I containing the V1
and V2 domains (Table 1; Figure 1). The shortest fragment (F)
extended from amino acid position 115 to 211, and included the
V1/V2 stem and the entire V1 and V2 loops. MAbs 1025 and
6E10 (isolated from a mouse immunized with IIIB-rgp140) failed
to bind to the V1/V2 fragment but only recognized the largest
(fragment I) that included the V1 to C3 domains (residues 104 to
371). Isotype analysis showed that all of the MAbs were of the
IgG1 isotype, with the exception of 1022, which was IgG2a, and
1029, which was IgG2b.
To determine whether the V2 MAbs recognized linear or
conformation-dependent epitopes, MAb binding to unfolded,
reduced and carboxymethylated MN-rgp120 (RCM-rgp120) was
examined. It was found (Table 1) that six of the nine MAbs tested
(6E10, 1017, 1022, 1025, 1028, and 1029) had no reactivity with
RCM-rgp120; two MAbs, 1019 and 1027, gave weak binding to
RCM-rgp120; and one MAb (1088) exhibited strong reactivity
with the denatured rgp120. These results demonstrated that the
immunization and screening procedure employed favored the
Figure 1. Fragments of gp120 used for epitope mapping studies. Fragments of the gp120 gene were selected based on the two-dimensional
structure of Leonard et al. [54] and fused to the signal sequence and 27 N terminal amino acids of glycoprotein D from type 1 herpes simplex virus.
The fragments were expressed in 293 cells, and cell culture supernatants containing the secreted fragments were screened by ELISA for MAb binding.
MAb binding to fragments A–E localized epitopes outside of the V1 and V2 domains; MAb binding to fragments F–I localized epitopes that depended
on the V1 and V2 domain.
doi:10.1371/journal.pone.0039045.g001
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epitopes.
Further information regarding the specificity of the V2 MAbs
was obtained in rgp120 cross-reactivity studies. In these experi-
ments, the MAb binding to recombinant gp120 from seven diverse
isolates of HIV-1 (MN, IIIB, NY5, JRCSF, A244, Z321, and Z6)
was measured. The results obtained (Table 1) indicated the cross-
reactivity was extremely limited, with six of the MAbs (1017, 1019,
1022, 1025, 1027, and 1088) reacting exclusively with MN-
rgp120. MAbs 1028 and 1029 bound both MN-rgp120 and IIIB-
rgp120, whereas the 6E10 MAb bound the MN, IIIB, and JRCSF
derived proteins. In control experiments (data not shown), MAb
1034, directed to the MN V3 domain, bound rgp120 from the
MN, IIIB, NY5, JRCSF, and Z321 isolates. These results
demonstrated that the V2-directed MAbs exhibited a high degree
of strain specificity.
In vitro neutralization activity
We found (Table 1) that six of the nine MAbs demonstrated
virus neutralizing activity. Of these, three (1019, 1027, and 1017)
had weak neutralizing activity (IC50$17 mg/mL) against the MN-
3 strain of HIV-1. Two (1088, 1025) had potent neutralizing
activity against the MN-3 strain (IC50 of 0.07 and 6.25 mg/mL,
respectively). Finally, the 6E10 MAb neutralized only the IIIB
strain of HIV-1 with an IC50 of 2.0 mg/mL [27]. Of these, the
1088 MAb was the most potent, with an IC50 in the same order of
magnitude as the positive control antibodies directed to the V3
domain (1026) and the CD4 binding site (b12). The prototypic
broadly neutralizing antibody to the V2 domain, PG9, had no
neutralizing activity in this assay and was unable to bind to
purified MN-rgp120 by ELISA (data not shown). Interestingly the
1088 antibody was the only V2 MAb that exhibited strong
reactivity with denatured (reduced and carboxymethylated) gp120
indicating that it recognizes a conformation-independent epitope.
Inhibition of rgp120 binding to CD4 by V2 MAbs
The ability of the nine V2 directed MAbs to inhibit binding of
[
125I]-MN-rgp120 to cell surface CD4 (Supplemental Figure S1)
was measured in assays similar to those described previously [28].
MAb 1088 completely inhibited the binding of MN-rgp120 to
CD4 with an IC50 of 1.0 mg/mL, whereas MAbs 1017, 1019,
1025, 1027, 1028, 6E10, and 1029 exhibited partial (i.e., 30%)
inhibition at a concentration of 10.0 mg/mL and gave no more
than 50% inhibition even at antibody concentrations exceeding
100 mg/mL. The CD4-blocking activity was apparent for the 1088
MAb in cell surface binding assays and in ELISA assays; however,
the CD4-blocking activity by the other MAbs was apparent only in
the cell surface binding assay. These data suggest that MAbs to the
V1/V2 region of gp120 can alter the binding of rgp120 to CD4,
and that some MAbs (e.g., 1088) have potent CD4 blocking
activity and potent neutralizing activity.
Cross-competition studies
Competitive binding assays (Figure 2) provided data on the
specificity of the different MAbs. In these studies, unconjugated
MAbs were allowed to react with rgp120-coated microtiter dishes
followed by a second incubation with horseradish peroxidase
(HRPO) labeled V2 MAbs. Inhibition of greater than 50% was
considered significant and was defined as directly competitive.
Based on the competitive binding data (Figure 2), the MAbs could
be divided into five distinct competition groups (A, B, C, D, and
E). Group A consisted of MAbs 1019 and 1027, whereas group B
included antibodies 1017, 1022, 1028, and 1029. MAbs 1088,
1025, and 6E10 represented distinct groups designated C, D, and
E, respectively. MAbs 1019, 1027, and 1025 were notable in that
they competed for binding with all of the V2 region MAbs
described in this paper.
Table 1. Properties of V2 region monoclonal antibodies.
MAbs Isotype RCM-rgp120
HIV rgp120
Binding CD4 Blocking Neutralization (mg/mL) Epitope Localization
1019 IgG1 +/2 MN + 23 V1, V2
1027 IgG1 +/2 MN + 17 V1, V2
1017 IgG1 2 MN + 23 V1, V2
1029 IgG2b 2 MN, IIIB + .25 V1, V2
1022 IgG2a 2 MN 2. 25 V1, V2
1028 IgG1 2 MN, IIIB + .25 V1, V2
1088 IgG1 +++ MN ++ 0.07 V1, V2
1025 IgG1 2 MN + 6.25 V1, V2, C2, V3, C3
6E10* IgG1 2 MN, IIIB, JRCSF + 2.0 V1, V2, C2, V3, C3
1026 IgG1 ND MN, IIIB, JRCSF 2 0.01 V3
b12 IgG1 ND ND ++ 0.02 C2, C3, C4, C5
PG9 IgG1 ND ND 2. 25 V2
RCM-rgp120, indicates the ability of MAbs to bind to denatured (reduced and carboxymethylated) gp120. HIV rgp120 binding, indicates the ability of MAbs to bind to
recombinant gp120 from the MN, IIIB and JRCSF strains of HIV in an ELISA format. CD4 blocking represents a summary of the data provided in Supplemental Figure S1.
Neutralization data represents the MAb concentration (mg/mL) required for 50% inhibition (IC50) of infectivity by the MN-3 strain of HIV-1 in the TZM-bl neutralization
assay (Materials and Methods) with the exception of the 6E10 MAb (*) where neutralization titers were measured using the IIIB strain of gp120 as described previously
[27]. Controls for the assays (italic) included MAbs 1026, b12 and PG9. ND, indicates not done. Epitope localization, summarizes the minimal gp120 structure required for
antibody binding based on MAb reactivity with the gp120 fragments shown in Figure 1.
doi:10.1371/journal.pone.0039045.t001
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We next characterized the epitopes recognized by these MAbs.
Because most of the MAbs exhibited weak binding to a MN-
rgp120 fragment consisting of only the V2 domain (data not
shown), we considered the possibility that the epitopes were
contained entirely in this region. Our initial strategy depended on
site-directed mutagenesis, where naturally occurring sequence
polymorphisms were incorporated into MN-rgp120 based on
comparisons of the sequence of MN-rgp120 with envelope
proteins from strains (Figure 3) that failed to bind the V2 MAbs.
One advantage of this strategy is that it relied on naturally
occurring mutations used by the virus to escape the immune
response, and avoided unphysiologic substitutions that were more
likely to disrupt the structure of the V2 domain. In the first series
of MN-rgp120 variants, we substituted residues from HIV-1
envelope proteins unable to bind the MAbs into the MN-rgp120
sequence. The panel consisted of proteins with the following
replacements: G166R, M169V, L176F, E182V, and P183S
(Table 2). A second series of experiments consisted of single and
double alanine (A) mutations where charged residues were
replaced by the non-polar alanine residue. These included
D167A-K168A, E172A, K178A, and E182A. In control experi-
ments, variants of MN-rgp120 containing mutations in regions
outside the V2 domain that were described previously [27], were
also assayed (data not shown). The results of these studies
identified six different antibody specificities.
The binding of the competition group A antibodies, 1019 and
1027, could be inhibited by the naturally occurring G166R
mutation and the double Ala mutation of D167A- K168A
(Table 3). These data did not allow us to know whether the
D167A-K168A mutations, alone or in combination, are respon-
sible for inhibiting the binding of these MAbs. We found that the
binding of these MAbs was unaffected by the M169V and E172A
mutations which are in close proximity to positions 166–168.
Based on these data, our results allowed us to define an epitope
termed MN.V2.1 that involves residues G166, D167, and/or
K168 (Table 4). Examination of the consensus sequence for Clade
B gp120s from the VAX004 trial (1024 sequences) and the Keele
dataset (2744 sequences) of viruses from new infections [29]
(Figure 4) suggests that G at position 166 is rare and occurs only at
4–6% of clade B isolates, whereas R at this position occurs in 65–
72% of clade B viruses. This mutation may explain the lack of
cross-reactivity and cross-neutralizing activity of these MAbs with
envelopes from other strains of HIV-1.
We next examined the competition group B MAbs (Table 3).
We found that the K178A and P183S mutations, independently,
inhibited the binding of all four of the group B MAbs (1022, 1028,
1017, and 1029). Therefore these two mutations define a second
epitope, termed MN.V2.2, that is at least ten amino acids away
from the MN.V2.1 epitope (Table 4). Although both positions in
the MN.V2.2 epitope are polymorphic, K at position 178 and P at
position 183 are the most common amino acids at these positions
among clade B viruses (Figure 4). Further analysis showed that
competition group B included a second epitope, termed MN.V2.3,
that was defined by the radical E182V mutation present in the
MN envelope protein, but few (0–5%) other clade B envelopes
(Table 4 and Figure 4). This mutation inhibited the binding of
MAbs 1022 and 1028 by 76% and 94%, respectively, whereas the
binding of the other competition group B MAbs was not inhibited
by the E182V mutation. The 1028 MAb in competition group B
was unique in that it cross-reacted with IIIB-rgp120, but the basis
for this differential recognition is not yet known. Thus the
MN.V2.3 epitope appears to be a discontinuous epitope, where
additional contact residues shared between MN- and IIIB-rgp120s
are required for the binding of this MAb (Table 4).
Competition group C is represented by MAb 1088. This MAb
was unique in that it recognized a conformation-independent
epitope, as indicated by its ability to bind RCM-rgp120, and by
the fact that it exhibited potent, type-specific, neutralizing activity
(Table 1). In addition, this MAb had the most potent CD4-
blocking activity (IC50=1.0 mg/ml) of any of the V2-specific
MAbs isolated. Like the MN.V2.2 and MN.V2.3 epitopes, binding
by this antibody was independently inhibited by the K178A and
P183S mutations, but was unaffected by the E182V mutation.
Based on its binding to denatured gp120, its competition pattern,
and its biologic activities, this antibody clearly represents a fourth
epitope, MN.V2.4 (Table 4). Interestingly, the K178A, E182V,
Figure 2. Competitive binding of monoclonal antibodies. Each
monoclonal antibody was labeled with horseradish peroxidase (HRPO).
The ability of a large excess of each unlabeled antibody to inhibit the
binding of HRPO MAbs was measured. Inhibition of greater than 50%
was considered significant and was defined as directly competitive.
Isotype matched antibodies to the V3 domain (1034) and the C4
domain (1024) served as negative controls. Data represent percentage
of inhibition: red, 90–100%; orange, 70–89%; yellow, 50–69%; green,
,50%.
doi:10.1371/journal.pone.0039045.g002
Figure 3. Alignment of V2 domains of HIV-1 envelope proteins
that differed in binding V2 MAbs. Sequences from the envelope
proteins used in ELISA assays to detect the binding of V2 MAbs were
aligned. Homologous sequences were shaded in blue. Plus (+), indicates
location of sites selected for mutagenesis. Numbering is provided with
reference to the sequence of the HXB2 envelope protein.
doi:10.1371/journal.pone.0039045.g003
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161 170 180
M N I T TSI GDKM QKEYALLYKLDI EPI DN
G 1 6 6 R - - ---R --- -----------------
G166R, E182V, P183S - - - - - R - - - - - - - - - - - - - - - V S - - -
G166R, M169V - - - - - R - - V - - - - - - - - - - - - - - - - -
G166R, M169V, E182V, P183S - - - - - R - - V - - - - - - - - - - - - V S - - -
D167A, K168A - - - - - - A A - - - - - - - - - - - - - - - - - -
M169V - - - - - - - - V - - - - - - - - - - - - - - - - -
E 1 7 2 A - - ------- --A --------------
L176F - - - - - - - - - - - - - - - F - - - - - - - - - -
K 1 7 8 A - - ------- --------A --------
E 1 8 2 A - - ------- ------------A ----
E 1 8 2 V - - ------- ------------V ----
P183S - - - - - - - - - - - - - - - - - - - - - - S - - -
E182V, P183S - - - - - - - - - - - - - - - - - - - - - V S - - -
E182V, P183V - - - - - - - - - - - - - - - - - - - - - V V - - -
doi:10.1371/journal.pone.0039045.t002
Figure 4. Frequency of sequence polymorphisms at positions in the V2 domain recognized by monoclonal antibodies to MN-
rgp120. Letters represent standard single letter amino acid codes. GAP indicates the frequency of a deletion at a given position. Subscripts represent
the percentage of sequence polymorphism at a single position in each dataset. Positions are numbered according to the HXB2 reference sequence.
The VAX004 dataset includes 1047 clade B sequences from 349 individuals. The Keele data set represents 2744 clade B sequences from 102
individuals. Residues circled in blue indicate amino acids present in the MNGNE strain of HIV-1. VAX004 data obtained from Pe ´rez-Losada et al., 2010
[60], using data listed in the GSID HIV Data Browser http://www.gsid.org/gsid_hiv_data_browser.html. Sequences of clade B envelope proteins from
new infections were obtained from Keele et al. [29] using data listed in the Los Alamos HIV Sequence Database http://www.hiv.lanl.gov/content/
sequence/HIV/mainpage.html.
doi:10.1371/journal.pone.0039045.g004
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conserved a4b7 recognition sequon, LDI/V, spanning positions
179–181 [23]. Therefore these MAbs appear to have the potential
to inhibit the binding of gp120 to the a4b7 receptor.
The competition group D MAb, 1025, resembled the compe-
tition group A antibodies in that it competed for binding with all of
the V2 MAbs in this study (Figure 2). However, it differed from the
competition group A antibodies in that it required the C2, V3, and
C3 domains, as well as the V1 and V2 domains, and it exhibited
modest virus neutralizing activity. Mutational analysis showed that
two mutations, E172A and L176F, uniquely resulted in an 87%
and 95% reduction, respectively, in binding of this MAb. These
results demonstrated that the 1025 MAb recognized a distinct new
epitope, MN.V2.5 (Table 4). Examination of the HIV-1 sequence
database revealed that both positions were polymorphic, with V or
E most commonly occurring at position 172 and F most
commonly occurring at position 176 (Figure 4). The 1025 MAb
was also unique in that it was the only MAb that was insensitive to
the double mutant E182V-P183S, as well as the triple mutant
G166R- E182V-P183S. Thus this epitope is clearly different from
the other epitopes described and seems to recognize a site located
between the MN.V2.1 and MN.V2.2 epitopes.
The competition group E antibody 6E10, which was isolated
from a mouse immunized with IIIB-rgp140 [27], cross-reacted
with rgp120 from the IIIB, MN and JRCSF isolates, and
neutralized the homologous IIIB isolate. Like the competition
group A MAbs, the binding of this antibody was inhibited
independently by the G166R mutation. However, like the
competition group B mutants, the binding of 6E10 was also
inhibited by the K178A mutation. These data suggest that the
6E10 MAb reacts with a distinct epitope termed MN.V2.6 that
overlaps the binding sites of the group A and group B epitopes
(Tables 3 and 4). Like the 1025 MAb, this antibody appeared to
recognize a conformation-dependent, discontinuous epitope that
required the C2, V3, and C3 domains for binding as well as the
V1 and V2 domains.
Finally, we examined the effect of combining multiple
mutations. We observed that several double and triple mutants
appeared to prevent the binding of most of the V2 antibodies in
the panel. We found that the E182V-P183S mutant and the
E182V-P183V mutant prevented the binding of all of the MAbs in
the panel except 1025, whereas other double mutants such as
G166R-M169V and D167A-K168A selectively inhibited MAb
binding. This result suggested that positions 182 and 183 are
unique in that they appear to be critically important for
maintaining a unique conformation or structural feature important
for the binding of all of the MAbs in this study except for 1025. In
view of this observation, it is not surprising that the triple mutant
G166R-E182V-P183S similarly prevented the binding of eight of
the nine MAbs in this study. As noted above, positions 182 and
Table 3. Relative binding of V2 MAbs to MN-rgp120 V2 mutants.
Group A Group B Group C Group D Group E Control Mutations
1019 1027 1022 1028 1017 1029 1088 1025 6E10 1034
0.00 0.00 0.60 0.62 0.64 0.63 0.63 0.53 0.03 0.68 G166R
0.00 0.00 0.00 0.01 0.09 0.11 0.00 0.67 0.00 0.87 G166R, E182V, P183S
0.21 0.00 0.88 0.86 0.88 0.85 0.83 0.79 0.55 0.86 G166R, M169V
0.12 0.00 0.00 0.07 0.21 0.17 0.01 0.89 0.69 0.99 G166R, M169V, E182V,
P183S
0.00 0.00 1.24 1.26 1.20 1.14 1.19 1.13 1.15 1.21 D167A, K168A
1.17 1.05 1.12 1.21 1.23 1.21 1.15 1.10 1.73 1.15 M169V
1.91 2.13 1.68 1.57 1.49 1.40 1.53 0.13 2.25 1.30 E172A
0.96 1.00 1.13 1.03 1.08 1.02 1.03 0.05 0.94 0.89 L176F
1.06 1.09 0.00 0.00 0.00 0.05 0.00 1.05 0.00 1.04 K178A
0.96 1.11 1.16 1.17 1.15 1.10 1.09 1.05 1.01 1.06 E182A
0.75 1.26 0.24 0.06 1.23 0.72 0.78 1.17 1.45 0.98 E182V
0.67 1.04 0.00 0.24 0.15 0.28 0.00 0.87 0.28 1.00 P183S
0.34 0.45 0.00 0.06 0.13 0.15 0.01 0.71 0.01 0.72 E182V, P183S
0.07 0.14 0.00 0.20 0.35 0.19 0.08 0.34 0.00 0.61 E182V, P183V
Data represent ratios of ELISA results where MAb binding to envelope proteins with the mutations indicated was compared to binding of the wildtype MN-rgp120.
Significant differences in MAb binding are represented by underlined numbers. Percentage inhibition is calculated according to the following equation: (1 – binding to
mutant/binding to MN-rgp120)6100.
doi:10.1371/journal.pone.0039045.t003
Table 4. Summary of V2 epitopes recognized by Murine
MAbs to MN-rgp120.
MAbs
Competition
Group
Contact
Residues Epitope
1019 A G166, D167, K168 MN.V2.1
1027 A G166, D167, K168 MN.V2.1
1017 B K178, P183 MN.V2.2
1029 B K178, P183 MN.V2.2
1022 B K178, E182, P183 MN.V2.3
1028 B K178, E182, P183 MN.V2.3
1088 C K178, P183 MN.V2.4
1025 D E172, L176 MN.V2.5
6E10 E G166, K178, P183 MN.V2.6
doi:10.1371/journal.pone.0039045.t004
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LDI spanning position 179–181.
Inhibition of gp120 binding to a4b7
We next investigated the potential of the MAbs to the V2
domain to block the binding of MN-rgp120 to the a4b7 receptor.
For this purpose we selected the RPMI-8866 B cell lymphoma cell
line [30,31] that is known to express a4b7, but does not express
CD4, the receptor for HIV-1. By using a cell line lacking CD4, we
avoided the necessity of using anti-CD4 antibodies to block gp120
binding to CD4 as has been described in previous studies where
the binding of gp120 to a4b7 was measured [23]. The binding of
MN-rgp120 to a4b7 was carried out with the use of biotinylated
MN-rgp120 and detected by flow cytometry using APC-conjugat-
ed streptavidin. In preliminary studies, we measured the binding of
MN-rgp120 to the RPMI-8866 cells and demonstrated the
specificity of this binding by showing that binding could be
inhibited by antibodies to a4b7 or by lowering the concentration
of Ca
2+ and Mn
2+ (data not shown) which are essential ions for the
binding of a4b7 to its normal receptor, MAdCAM. In these
experiments we screened several MAbs raised against a4b7 (see
Materials and Methods), and found that the FIB504.64 MAb was
particularly effective in blocking MN-rgp120 binding to a4b7. We
then examined the ability of MAbs to the V2 domain to inhibit
binding to a4b7. For these studies, we utilized antibodies from all
five competition groups. We found (Figure 5) that antibodies from
competition groups A, C, and E significantly (p,0.05) inhibited
MN-rgp120 binding to a4b7. Interestingly, the A, C, and E groups
all depended on positions 178 and 183 which flanked the a4b7
binding site (LDI) located at positions 179, 180, and 181. In
contrast, the group D MAb, 1025, whose binding is dependent on
positions 172 and 176, was ineffective in blocking binding to a4b7.
We cannot explain the inability of the group B MAb 1022 to block
a4b7 binding, since it also recognizes positions 178, 182, and 183.
Thus, antibodies from three of five competition groups were able
to block the binding of MN-rgp120 to a4b7 binding in this assay,
and the 1027, 1088, and 6E10 MAbs were as effective as the
FIB504.64 antibody in blocking binding to a4b7.
Discussion
In the present study, we used a novel strategy to characterize the
binding specificity of nine MAbs reactive with the V2 domain of
MN-rgp120. Initial localization of epitopes was carried out with a
series of overlapping, glycosylated fragments of gp120 expressed in
mammalian cells. Epitope fine mapping was determined by site-
directed mutagenesis where the impact of naturally occurring
sequence polymorphisms on antibody binding to the V2 domain
was measured. In addition, we describe a novel assay using cells
from the RPMI-8866 B-cell lymphoma to measure the binding of
gp120 to the a4b7 integrin and the ability of antibodies to the V2
domain of gp120 to inhibit this binding. Because the RPMI-8866
cells do not express CD4, it eliminates the need to block the high
affinity binding of gp120 to CD4 that was a significant
complication in previous studies of gp120 binding to a4b7 [23].
Comparison of the MAbs revealed differences in cross-reactivity
with envelopes from different strains, CD4 blocking activity, virus
neutralizing activity, antibody competition, and the ability to block
gp120 binding to a4b7. Site-directed mutagenesis identified eight
positions in the V2 domain (166, 167, 168, 172, 176, 178, 182, and
183) that were critical for binding of one or more of the MAbs
(Figure 6). These could be divided into two main clusters. One
cluster involved residues 166–168, recognized by the 1019 and
1027 MAbs. These positions had previously been identified as
being important for the binding of several potent neutralizing
MAbs (e.g. PG9, 2909, CAP254) [32,22,20,33,21]. Five of the nine
MAbs (1022, 1028, 1017, 1029, and 1088) recognized another
cluster of amino acids (178–183) immediately adjacent to the a4b7
binding site [23]. One MAb (6E10) was unique in that it appeared
to recognize amino acids from both clusters.
The structure of a scaffold comprising the V1 and V2 domains
of gp120 bound to the broadly neutralizing PG9 MAb has recently
been elucidated [34]. It was found (Figure 7) that the V1 and V2
domains consist of four anti-parallel b-sheets (A, B, C, and D).
Interestingly the two immunodominant clusters of amino acids
important for the binding of the mouse MAbs described in this
study occurred at the opposite ends of the C strand and included
residues from the turn at the B–C strand junction and the
disordered peptide of the C–D connecting loop. The B–C turn
includes positions 166, 167, and 168 that were important for the
binding of the 1019 and 1027 murine MAbs described in this
Figure 5. Inhibition of MN-rgp120 binding to a4b7b y
monoclonal antibodies to the V2 domain. Biotinylated MN-
rgp120 was incubated with monoclonal antibodies to the V2 domain
of gp120 for 1 hr at room temperature. Antibodies representative of the
five V2 competition groups were tested: Group A, 1019 and 1027;
Group B, 1022; Group C, 1088; Group D, 1025; Group E, 6E10. The
mixture was then added to cells and incubated for 1 hr at 4uC. After
washing, the cells were incubated with APC-conjugated streptavidin to
detect gp120 binding. The amount of gp120 binding to cells was
measured by flow cytometry and statistical analysis was carried out by
one way ANOVA including a Bonferroni correction. The binding of MN-
rgp120 to a4b7 without added MAbs (control) is indicated by the black
bar. Statistically significant inhibition of MN-rgp120 binding (p,0.05) is
indicated by gray bars; inhibition that does not reach statistical
significance is indicated by white bars. Inhibition of MN-rgp120 binding
by the FIB504.64 MAb to a4b7 was measured as described in Materials
and Methods.
doi:10.1371/journal.pone.0039045.g005
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neutralizing human MAbs [35,34,36]. The second cluster of
epitopes overlaps the connecting loop between the C and D
strands and is in close proximity to the a4b7 binding site (positions
179–181). Five of the nine MAbs described in this study (1022,
1028, 1017, 1029, and 1088) were found to recognize amino acids
(residues 178–183) immediately adjacent to the a4b7 binding site.
Recent studies have shown that the central aspartic acid (D180)
residue within the a4b7 recognition sequence (LDI/V) also
appears to be an essential part of the conformational masking
mechanism [37] used to shield neutralizing epitopes from
neutralizing antibodies. Previous studies have referred to the V2
domain as the ‘‘global regulator of neutralization sensitivity’’
[18,19] and have shown that the V2 domain interacts with other
regions of gp120. Thus, the stem of the V2 domain is adjacent to
the CD4 binding site [38,39] and mutations in the V2 domain are
known to affect CD4 binding as well as the binding of neutralizing
antibodies that recognize both the V3 domain and the CD4
binding site [40,41]. Astonishingly, deletion of the entire V2
domain can sometimes increase sensitivity to neutralization by
antibodies to other regions while preserving virus infectivity
[17,19]. Finally, replacement of the V2 domain of a neutraliza-
tion-resistant virus with the V2 domain of a neutralization-
sensitive virus is able to confer the neutralization-sensitive
phenotype [18].
Neutralizing MAbs targeting the V2 domain have been isolated
from mice and rats immunized with recombinant envelope
proteins, and from chimpanzees and humans infected with HIV-
1 ([40–46,32,47,33]. Until 2009, most of the neutralizing MAbs to
the V2 domain were thought to be strain-specific, and less potent
than antibodies to the V3 domain and CD4 binding site [48]. The
recent isolation of several broadly neutralizing human MAbs to
the V2 domain [22,35,49], as well as the correlation observed
between protection and antibodies to the V2 domain in the
RV144 trial [11], has rekindled interest in the V2 domain as a
target for HIV-1 vaccine development. The prototype for broadly
neutralizing antibodies to the V2 domain is the PG9 MAb, isolated
from an elite neutralizer infected with a clade A virus [22]. The
binding of this MAb appears to be dependent on sequences in both
the V2 and V3 domains. Interestingly, binding by PG9 and other
broadly neutralizing MAbs to the V2 domain is dependent on N-
linked carbohydrate at positions 156 and 160 in the B strand, as
well as a number of specific amino acids (e.g., residues 158, 159,
162, 167, 168, 173, 176, and 181) [22,35,34,49]. Although the
Figure 6. Location of amino acids critical for the binding of monoclonal antibodies to the V2 domain of gp120. A diagram of the
gp120 V2 domain, incorporating amino acids from the MNGNE strain of HIV-1, was created based on the disulfide structure of Leonard et al. [54]. The
locations of the amino acids required for the binding of the MAbs to the V2 domain described in this paper, as well as 697-D [43], 2909 [47] and the
potent PG9 and 16 [22] neutralizing antibodies are indicated by colored dots. Group, indicates competition group and epitopes from Table 4. Arrows,
indicate the location of three radical amino acid polymorphisms found in MN-rgp120 compared to consensus clade B clinical isolates [60] and Keele
[29]. Data for this figure was derived from previously published results [47,22,33].
doi:10.1371/journal.pone.0039045.g006
Monoclonal Antibodies to the MN-rgp120 V2 Domain
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39045impact of glycosylation at these positions was not examined for the
murine MAbs described in the study, both the MN- and IIIB-
rgp120 immunogens used to elicit these MAbs possessed
glycosylation sites at positions 156 and 160, and lacked a
glycosylation site at position 162. The inability of PG9 to
neutralize the MN strain of HIV-1 observed in these studies
(Table 1) as well as its poor reactivity with MN-rgp120 by ELISA
(Berman and Yu, unpublished results) may be due to differences in
glycosylation at these positions.
Several studies have shown that neutralizing antibodies to the
V2 domain are present in sera from HIV-infected humans. Walker
et al. [20] reported that approximately 21% of the neutralizing
activity in nineteen donors screened for high neutralization titers
could be attributed to V2 MAbs with specificities similar to PG9
and PG16. Moore et al. [21] analyzed a potent neutralizing sera
(CAP256) from a clade C infected individual and found much of
the neutralizing activity was directed to the V2 domain at an
epitope that overlapped, but was distinct from, the epitopes
recognized by PG9 and PG16. This study reported that the
binding of these antibodies was dependent on F159, N160, L165,
K166, D167, and K169. The data from the present studies
similarly show the importance of positions 166, 167, and 168 in
the binding of MAbs from humans and mice. Although lysine (K)
at position 169 was important for the binding of the sera from
CAP256, the substitution of methionine (M) for valine (V) at
position 169 in the V2 domain of the MN envelope protein had no
effect on the binding of any of the MAbs in this study.
An important finding of this study was that four of the epitopes
(MN.V2.2, MN.V2.3, MN.V2.4, and MN.V2.6) depended on
positions 178, 182, and 183, adjacent to the highly conserved
LDV/I sequon of the a4b7 binding site in the C–D connecting
loop. The observation that the double mutation E182V-P183S
blocked the binding of all of the MAbs described in this study (with
the exception of 1025) suggests that these two residues are part of a
structural element required for the functional conformation of the
V2 domain. This result is in agreement with our previous
observation [37] that the replacement of D with N at position 180
(HXB2 numbering) in the 108051 envelope protein induces a
conformational change that markedly increases neutralization by
inhibitors targeting the CD4 binding site in gp120 (e.g., CD4-IgG)
and the MPER domain in gp41 (e.g., MAbs 2F5 and 4E10). The
fact that positions 178, 182, and 183 are located on either side of
the a4b7 recognition sequence suggests that MAbs to all four
epitopes have the potential to block gp120 binding to a4b7b y
steric interactions. If antibodies binding to these residues are found
in sera from the RV144 trial, then non-neutralizing, a4b7-
blocking antibodies may represent a possible correlate of
protection. Studies are underway to analyze sera from the
VAX003 and RV144 trials for antibodies of this type. In two
previous Phase 3 HIV vaccine trials [50,9], we reported that the
AIDSVAX B/B and AIDSVAX B/E vaccines containing MN-
rgp120 elicited robust immune responses to linear epitopes in the
V2 domain, as measured by binding to synthetic peptides from the
MN and A244 strains of HIV-1. Both peptides span the regions
that contain the epitopes recognized by the MAbs described in this
paper, but all except 1088 fail to bind to these.
Given the fact that MN-rgp120 is able to stimulate the
formation of conformation-dependent antibodies to the V2
domain, it is surprising that we didn’t observe greater cross-
reactivity and greater neutralizing activity. Several possible
explanations may account for this. First, there were several radical
amino acid polymorphisms in the MN-rgp120 immunogen that
are uncommon in clade B isolates (Figure 4). These include glycine
(G) rather than arginine (R) at position 166, leucine (L) rather than
phenylalanine (F) at position 176, and glutamic acid (E) rather
than valine (V) at position 182. These may account for the strain
specific anti-V2 response. Second, it is possible that the
monomeric immunogens used in the AIDSVAX vaccines were
Figure 7. Location of epitopes recognized by monoclonal antibodies to the V2 domain of MN-rgp120. A diagram of the V1/V2 domains
of gp120 taken from the 3U4E structure of McLellan et al. [34] is shown. The V1 and V2 domain include four anti-parallel strands (colored arrows) with
a disordered loop region (dotted line) between the C and D strand. Light gray lines indicate disulfide bonds. The location of carbohydrate essential
for the binding of the PG9 MAb is shown in red. The approximate locations of the two immunodominant clusters of residues critical for the binding of
eight of the nine murine MAbs described in this study are indicated by shaded ovals. Thus the 166–168 cluster of amino acids occurs at the turn
located at the B–C junction. The epitopes clustering in the region of residues 178–183 occur in the disordered peptide connecting the C and D
strands on either side of D180, the central amino acid in the a4b7 binding site [23]. A linear diagram of the V2 domain and a listing of the sequence of
the V2 domain of MN-rgp120 is provided at the bottom of the figure.
doi:10.1371/journal.pone.0039045.g007
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interactions in the gp160 homotrimer, essential for the production
of some neutralizing antibodies to the V2 domain. Finally it is
possible that the immune response to the V2 domain elicited in
humans differs from that elicited in mice with respect to formation
of antibodies targeting carbohydrate-containing epitopes such as
PG9.
The results described in this paper add to our understanding of
the specificity of the immune response to the V2 domain of gp120.
They show that the antigenic structure of the V2 domain is
extraordinarily complex, containing at least eight to ten confor-
mation-dependent epitopes including the six described in this
paper along with those recognized by the PG9, PG16, 2909,
C108g, and 10/76b MAbs [46,51,47,22] and multiple conforma-
tion-independent epitopes. The studies described show that
antibodies to the V2 domain can inhibit the binding of MN-
rgp120 binding to a4b7 and highlight epitopes in the V2 domain
that deserve further investigation. This is particularly significant in
the context of the protection observed in the RV144 clinical trial,
compared to the lack of protection observed in the VAX003 and
VAX004 clinical trials. Such studies will help clarify the extent to
which the immune response to the V2 domain elicited by vaccine
antigens replicates the immune response to natural infection, and
may provide insights useful for the validation of antibodies to the
V2 domain as the factor responsible for protection in the RV144
trial.
Materials and Methods
gp120 sequences and nomenclature
The standard single letter code is used to designate the amino
acids. The numbering of amino acids in gp120 is provided with
reference to the standard HXB2 numbering system. The sequence
of the MN isolate incorporated in the MN-rgp120 immunogen
(MNGNE) has been described elsewhere (GSID HIV Data
Browser, http://www.gsid.org/gsid_hiv_data_browser.html). The
gp120 MNGNE is two percent different than the original MN
gp120 sequence published by Gurgo et al. [52]. The sequence of
IIIB reported in this paper was described by Muesing et al. [53].
All the conserved and variable domain assignments were based on
the 2D structure of gp120 [54].
HIV envelope proteins
The HIV envelope proteins including MN-rgp120 were
produced as described previously [1–3]. Purified MN-rgp120
protein was biotinylated by amine-coupling using the EZ-Link
TM
NHS Biotin kit (Pierce) following the manufacturer instructions. A
20-fold molar excess of EZ-Link
TM NHS Biotin reacted with MN-
rgp120 protein for 30 min at room temperature. The biotinylated
protein was then dialyzed against PBS to remove non-reacted
biotin. Purified MN-rgp120 was labeled with
125I as described
previously.
Monoclonal antibodies and immunoassays
Mouse monoclonal antibodies reactive with the V2 domain of
MN-rgp120 were identified from a collection of thirty-six
monoclonal antibodies produced in the mid-1990s at Genentech,
Inc. (S. San Francisco, CA) [27,28] and purified using Protein A
Sepharose (Pharmacia, Piscataway, NJ). MAbs were conjugated to
horseradish peroxidase (HRPO) according to the method of
Nakane et al. [55]. The cross-reactivity of the MAbs to
recombinant gp120s from clade B (IIIB, NY5, JRCSF, and
MN), clade A (Z321), clade D (Z6), and clade E (A244) isolates of
HIV-1 was determined by ELISA, as described previously [27,28].
The ability of the MAbs to inhibit the binding of [
125I]-labeled
MN-rgp120 to cell surface CD4 was measured as described
previously [28]. The binding of MAbs to chemically denatured
MN-rgp120 was determined by ELISA using reduced and
carboxymethylated gp120 [54]. MAbs to a4b7 integrins, including
the rat anti-b7 MAbs FIB21, FIB22, FIB30, FIB504, LS722, and
the anti-a4b7 mouse MAb, Act-1 [56] were a gift from Eugene C.
Butcher (Stanford University School of Medicine, Stanford, CA).
Site-directed mutagenesis and expression of MN-rgp120
V2 mutants
Site-directed mutagenesis of regions in the MN-gp120 V2
region was performed using the method of Kunkel et al. [57]. The
pRKMN120 plasmid encoding the entire envelope protein of the
MN-gp120 was transformed into the dut
2ung
2 CJ236 E. coli
strain and then grown in the presence of MK107 helper phage for
the purpose of generating a single stranded DNA template. 33- to
40-mer oligonucleotides incorporating the desired mutation were
utilized to insert the mutations into the V2 region. The mutants
were transformed into bacteria and the colonies were screened by
sequencing (Sequenase 2.0, U.S. Biochemicals) to check for the
correct mutations. These plasmids containing the MN gp120 V2
mutants were then transfected into the 293 human embryonic
adenocarcinoma cell line using the calcium phosphate method
described by Graham and van der Eb [58]. After three days,
secreted rgp120 containing the V2 mutations was collected and
quantitated using a gp120 ELISA.
Expression of MN envelope fragments
Fragments of MN-rgp120 were expressed in mammalian cells as
described previously [28]. Briefly, selected fragments of MN-
rgp120 gene were generated by PCR and fused, in frame, at the 59
end to a fragment of the herpes simplex virus type 1 glycoprotein
D (gD-1) gene (containing the signal sequence and 27 amino acids
of the mature gD-1 protein) and at the 39 end to translational stop
codons. A 39 Xho1 site engineered into the gD-1 fragment allowed
for in-frame ligation of PCR-generated gp120 fragments. The
chimeric fragments were cloned into the pRK5 mammalian cell
expression vector containing the CMV promoter and enhancer
elements and an SV40 polyadenylation site. Calcium phosphate-
precipitated plasmid DNA encoding the chimeric gp120 fragments
was transfected in the embryonic kidney adenocarcinoma-derived
293 cell line (Invitrogen, Carlsbad, CA), and growth conditioned
cell culture medium was collected for immunoassays (described
below).
Localization of MAb binding sites using fragments of the
MN-rgp120
The ability of MAbs to bind to various fragments of MN-rgp120
was determined by ELISA. Three days after transfection, the 293
cell culture supernatants were harvested and the gp120 fragments
were captured onto wells of microtiter plates coated with a murine
MAb (5B6) specific for the gD-1 flag epitope. The ability of
HRPO-conjugated MAbs to bind to the captured fragments was
measured by ELISA. The cell culture supernatants containing the
MN-rgp120 fragments were then added to the wells and incubated
for 2 hr at room temperature. The plates were washed twice with
PBT (Phosphate-buffered saline with 0.05% Tween-20) and then
incubated for 2 hr at room temperature with a pre-titrated
amount of HRPO-labeled MAb. Plates were washed again in PBT
buffer and then developed with o-phenylenediamine tablets
(Sigma, St. Louis, MO) for 15 minutes. The reaction was stopped
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microtiter plate spectrophotometer at a wavelength of 492 nm.
Binding of V2 MAbs to MN-rgp120 V2 mutants
A capture ELISA similar to that described previously [59] was
used to measure the binding of MAbs to MN-rgp120 variants
mutated in various domains. Briefly, microtiter assay plates were
coated (5 mg/mL in PBS, overnight at 4uC) with an affinity
purified polyclonal sheep antisera (D7234, International Enzymes,
Fallbrook, CA) to a sequence in the C terminus of gp120. The
plates were blocked with PBS containing 0.7% bovine serum
albumin for 1 hr at room temperature. Equivalent amounts of the
tissue culture supernatants from the transiently expressed gp160
mutants were added and incubated for 2 hr at 37uC followed by
washing 3 times in PBT buffer. Various MAbs (0.16 mg in 100 ml),
diluted in a PBS BSA buffer, were added to each well and
incubated for 1.5 hours at 37uC. The plates were then washed in
PBT buffer and then incubated with HRPO-conjugated goat anti-
mouse IgG (1/2000 dilution in PBT) for 1 hr at room
temperature. The plates were developed with OPD and stopped
by the addition of 2.5N H2SO4.
MN-rgp120 CD4 blocking assays
The CD4 blocking assay was described elsewhere [27,28].
Briefly, Chinese hamster ovary cells continuously expressing full
length human CD4 were plated in 96 well dishes until 90%
confluent. [
125I]-labeled MN-rgp120 (2 nM) was mixed with
serially diluted MAbs and then transferred onto the cells. The
assay was performed in a 50:50 mix of F12/DMEM (Gibco,
Grand Island, NY) containing 10% fetal bovine serum, 0.01%
NaAzide and 12 mM HEPES. The mixture was allowed to react
with the cells for 2 hr, and then washed four times with assay
medium. The washed cells were then solubilized in 100 mL of 1.0
N NaOH for 30 min and 90 mL was removed for counting in a
gamma counter. The percentage of inhibition was calculated by
the equation 100-[100*(experimental – background)/(antibody
control – background)].
Virus neutralization assays
A colorimetric MT-2 syncytia inhibition assay, similar to that
described previously [27,28] was initially used to screen MAb
supernatants for neutralizing activity. For MAb characterization, a
standard TZM-bl neutralization assay was used to assess the ability
of V2 MAbs to neutralize pseudotyped virus from the MN-3 [10].
IC50 curves were calculated from serial 3-fold dilutions from 1/
20–1/43,740 in TZM-bl cells. The TZM-bl cells and the
pSG3
Denv expression plasmid were obtained from the NIH AIDS
Research & Reference Reagent Program (contributed by Drs.
John C. Kappes & Xiaoyun Wu). The MN-3 envelope expression
plasmid was a gift from Dr. David Montefiori. For standardization
of protocols, we used HIV-1 MN-3 pSG
Denv 293T/17 pseudo-
virus, a generous gift from Jochen Schmidt and Hagen Von
Briesen at the HIV Specimen Cryorepository, Fraunhofer Insitute
(IBMT), Sulzbach, Germany.
a4b7 binding assays
Purified MN-rgp120 protein was biotinylated as described
above. The binding of biotinylated MN-rgp120 to a4b7 was
carried out using the a4b7
+, b1
2 RPMI-8866 B lymphoma cell
line [30,31] kindly provided by Eugene C. Butcher (Stanford
University School of Medicine, Stanford, CA). Cells were grown in
RPMI-1640 supplemented with 10% FBS, L-glutamine, sodium
pyruvate, penicillin-streptomycin, non-essential amino acids and
2-mercaptoethanol. The binding of MN-rgp120 to a4b7 was
measured by flow cytometry. For this assay, Fc receptors on the
RPMI-8866 cells were first blocked by pre-treatment with rabbit
IgG. The cells were then incubated for 1 hr at 4uC with
biotinylated MN-rgp120 in staining buffer (0.5% BSA, 10 mM
HEPES, 150 mM NaCl, 100 mM CaCl2 and 1 mM MnCl2).
APC-conjugated streptavidin (BioLegend, CA) was used to detect
biotinylated gp120 binding to the cells. For blocking experiments,
MN-rgp120 (20 mg/ml) was pre-incubated with the V2 MAbs
(10 mg/ml) for 1 hr at room temperature and then added to the
cells. For blocking experiments with the integrin MAbs, cells were
pre-incubated with the integrin MAbs (10 mg/ml) for 30 min at
4uC, washed twice with 0.5% BSA in PBS and then the
biotinylated MN-rgp120 was added. Data were collected with a
FACSAria (Becton-Dickinson Biosciences, San Jose, CA) at the
UC Santa Cruz Flow Cytometry Facility and analyzed with
FlowJo 8.8.6. software (TreeStar).
Statistical analysis
Differences between the ability of MN-rgp120 to bind a4b7i n
the absence or presence of V2 antibodies were analyzed with one
way ANOVA with Bonferroni correction, using Prism 5.0
(GraphPad Software). P values of ,0.05 were considered to be
statistically significant.
Supporting Information
Figure S1 Inhibition of rgp120 binding to CHO cell lines
expressing CD4 by monoclonal antibodies to the V2
domain of gp120. CHO cells expressing membrane-bound
human CD4 were plated in 96-well microtiter plates until they
were 90% confluent. Serial dilutions of MAbs were pre-incubated
with a fixed amount of [
125I]-gp120 (2 nM) and then incubated
with the cells for 2 hr. The cells were then washed four times and
the cells solubilized in 100 mL of 0.1 N NaOH. Specific binding
was calculated as described previously [27]. MAb 1024, a CD4-
blocking antibody directed to the C4 domain of gp120, served as a
positive control.
(PDF)
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